GNTA Profile
Genenta Science S.p.A. is a clinical-stage biotechnology company based in Milan, Italy, specializing in the development of innovative hematopoietic stem cell gene therapies designed to target and treat solid tumors. The company's lead therapeutic candidate, Temferon, represents a pioneering approach in gene therapy, utilizing genetically modified stem cells to deliver interferon-alpha directly to cancer cells. Temferon is currently undergoing Phase 1/2a clinical trials for the treatment of glioblastoma multiforme, specifically targeting patients with an unmethylated MGMT gene promoter, a subgroup known for its poor prognosis and resistance to conventional therapies.
Beyond glioblastoma, Genenta Science is expanding the potential applications of Temferon to other challenging solid tumors. The company is also exploring its use in treating locally advanced hepatocellular carcinoma and intra-hepatic cholangiocarcinoma. This broader development strategy highlights Genenta's commitment to addressing a range of difficult-to-treat malignancies through its advanced gene therapy platform, which aims to enhance treatment efficacy and improve patient outcomes.
Founded in 2014, Genenta Science leverages its expertise in stem cell gene therapy to develop next-generation treatments for cancer. The company’s research focuses on harnessing the unique properties of hematopoietic stem cells to deliver targeted therapies that can address the limitations of existing cancer treatments. Genenta’s approach reflects a growing trend in biotechnology toward personalized and precision medicine, aiming to provide more effective and less toxic treatment options for patients with severe and complex cancers.
Headquartered in Milan, Genenta Science is positioned at the forefront of cutting-edge cancer research, with a dedicated focus on advancing its gene therapy pipeline through clinical development. The company's innovative approach and ongoing trials underscore its role in the evolving landscape of cancer treatment, with the potential to significantly impact the way solid tumors are treated in the future.
|
